首页> 外文期刊>Diabetology and Metabolic Syndrome >Effect of single tablet of fixed-dose amlodipine and atorvastatin on blood pressure/lipid control, oxidative stress, and medication adherence in type 2 diabetic patients
【24h】

Effect of single tablet of fixed-dose amlodipine and atorvastatin on blood pressure/lipid control, oxidative stress, and medication adherence in type 2 diabetic patients

机译:固定剂量氨氯地平和阿托伐他汀单片对2型糖尿病患者的血压/血脂控制,氧化应激和药物依从性的影响

获取原文
           

摘要

Background Oxidized low-density lipoprotein (LDL) plays central roles in the formation and progression of atherosclerotic lesions. Malondialdehyde (MDA)-modified LDL (MDA-LDL) is speculated to be generated as a result of oxidative stress in the human body. Because both amlodipine and atorvastatin have been reported to reduce oxidative stress, it is expected that both drugs would have a favorable influence to reduce oxidative stress. Objective The objective of this study was to investigate the effects of a single pill of amlodipine (5 mg)/atorvastatin (10 mg) on oxidative stress, blood pressure/lipid control and adherence to medication in patients with type 2 diabetes. Methods This combination tablet was administered to 29 patients (16 male), and MDA-LDL, blood pressure, lipid profile, renal/liver function, CPK, hs-CRP, adiponectin, BNP, and HbA1c were measured at baseline, 6, and 12 months, and baPWV and mean IMT were measured at baseline and 12 months. Medication adherence was examined using a questionnaire at 6 months. Results MDA-LDL was decreased significantly. LDL-C, TG, and Cr were significantly decreased at 6 and 12 months compared with baseline. eGFR was increased at 6 months, and urinary albumin/creatinine ratio was decreased at 12 months. BNP was decreased at 6 and 12 months, and adiponectin was increased at 12 months. Both mean IMT and baPWV were significantly decreased. The results of the questionnaire showed that 93% of patients were satisfied with this medication. No severe adverse event was observed. Conclusion This combination tablet controlled both hypertension and dyslipidemia well in type 2 diabetic patients. The deceases in mean IMT and baPWV might suggest the improvement of atherosclerosis by this medication, which could be caused by the reduction of oxidative stress measured by MDA-LDL. In addition, this medication is expected to improve medication adherence.
机译:背景氧化的低密度脂蛋白(LDL)在动脉粥样硬化病变的形成和发展中起着核心作用。丙二醛(MDA)改性的LDL(MDA-LDL)推测是由于人体氧化应激而产生的。由于已经报道了氨氯地平和阿托伐他汀均可以降低氧化应激,因此预期这两种药物都将对降低氧化应激产生有利的影响。目的本研究的目的是研究单药氨氯地平(5 mg)/阿托伐他汀(10 mg)对2型糖尿病患者的氧化应激,血压/血脂控制和药物依从性的影响。方法对29例患者(16例男性)进行联合片剂的测定,分别在基线,6岁和6岁时测定MDA-LDL,血压,血脂,肾/肝功能,CPK,hs-CRP,脂联素,BNP和HbA1c。 12个月,并在基线和12个月时测量baPWV和平均IMT。在6个月时使用问卷调查药物依从性。结果MDA-LDL明显降低。与基线相比,在第6和12个月时LDL-C,TG和Cr显着降低。 6个月时eGFR升高,而12个月时尿白蛋白/肌酐比值降低。在6个月和12个月时,BNP降低,而在12个月时,脂联素升高。平均IMT和baPWV均显着降低。问卷调查结果显示93%的患者对此药物感到满意。没有观察到严重的不良事件。结论该组合片剂可很好地控制2型糖尿病患者的高血压和血脂异常。平均IMT和baPWV的下降可能表明该药物可改善动脉粥样硬化,这可能是由MDA-LDL测定的氧化应激降低引起的。另外,该药物有望改善药物依从性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号